International Forum on typing and matching strategies in patients on anti‐CD38 monoclonal therapy

K. M. K. De Vooght, M. Lozano, J-L. Bueno, A. Alarc on, I. Romera, K. Suzuki, E. Zhiburt, A. Holbro, L. Infanti, A. Buser, H. Hustinx, V. Deneys, A. Fr elik, C. Thiry, M. Murphy, J. Staves, K. Selleng, A. Greinacher, J. M. Kutner, C. Bonet Bub, L. Castilho, R. M. Kaufman, M. E. Colling, P. Perseghin, A. Incontri, M. Dassi, D. Brilhante, A. Macêdo, C. Cserti-Gazdewich, J. M. Pendergrast, J. Hawes, M. N. Lundgren, J. R. Storry, A. Jain, N. Marwaha, R. R. Sharma

[1]  S. Ailawadhi,et al.  Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States. , 2017, Clinical therapeutics.

[2]  V. Deneys,et al.  Daratumumab joker thérapeutique, piège immunologique ! , 2017 .

[3]  S. Stowell,et al.  Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. , 2017, Blood.

[4]  G. Denomme,et al.  How do I work up pretransfusion samples containing anti‐CD38? , 2017, Transfusion.

[5]  S. Shunkwiler,et al.  Use of standard laboratory methods to obviate routine dithiothreitol treatment of blood samples with daratumumab interference , 2017, Immunohematology.

[6]  I. Krsnik,et al.  Daratumumab and Blood-Compatibility Testing. , 2016, The New England journal of medicine.

[7]  M. Murphy,et al.  International validation of a dithiothreitol (DTT)‐based method to resolve the daratumumab interference with blood compatibility testing , 2016, Transfusion.

[8]  M. Oostendorp,et al.  New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing , 2016, Current opinion in hematology.

[9]  H. Goldschmidt,et al.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[10]  A. Palumbo,et al.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[11]  M. Oostendorp,et al.  Dealing with anti‐CD38 (daratumumab) interference in blood compatibility testing , 2016, Transfusion.

[12]  P. Parren,et al.  When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy , 2015, Transfusion.

[13]  J. Laubach,et al.  Resolving the daratumumab interference with blood compatibility testing , 2015, Transfusion.

[14]  N. C. Price,et al.  The stabilities of various thiol compounds used in protein purifications , 1983 .